Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model

Abstract

Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive activity. To date, despite the mounting evidence implicating the potential diagnostic/prognostic and therapeutic value of maspin in breast and prostate carcinoma, the lack of a suitable animal model hampers the in vivo investigation on the role of maspin at different stages of tumor progression. In this study, we used MMTV/TGF-α transgenic mouse model to study the expression profile of maspin in mammary tumor progression. Histopathological examinations of MMTV/TGF-α transgenic mice revealed TGF-α expression leading to hyperproliferation, hyperplasia, and occasional carcinoma in mammary gland. Interestingly, when MMTV/TGF-α transgenic mice were breed to homozygocity, they also developed characteristic skin papillomas. Immunohistochemistry analysis of maspin expression in the breast tissues of TGF-α transgenic mice showed a direct correlation between down-regulation of maspin expression and tumor progression. The loss of maspin expression was concomitant with the critical transition from carcinoma in situ to invasive carcinoma. Subsequent in-situ hybridization analyses suggest that the down-regulation of maspin expression is primarily a transcriptional event. This data is consistent with the tumor suppressive role of maspin. Furthermore, our data suggests that MMTV/TGF-α transgenic mouse model is advantageous for in vivo evaluation of both the expression and the biological function of maspin during the slow multi-stage carcinogenesis of mammary gland.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Carpenter G, Cohen S . 1979 Annu. Rev. Biochem. 48: 193–216

  • Derynck R . 1988 Cell 54: 593–595

  • Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP . 1988 J. Exp. Med. 167: 670–675

  • Humphreys RC, Hennighausen L . 2000 Oncogene 19: 1085–1091

  • Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT . 1990 Cell 61: 1137–1146

  • Lenferink AEG, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL . 2000 Proc. Natl. Acad. Sci. USA 97: 9609–9614

  • Lin AW, Lowe SW . 2001 Proc. Natl. Acad. Sci. USA 98: 5025–5030

  • Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ . 1990 Cell 61: 1147–1155

  • McGowen R, Biliran Jr H, Sager R, Sheng S . 2000 Cancer Res. 60: 4771–4778

  • Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK . 1994 Cell. Growth Differ. 5: 1275–1982

  • Rose-Hellekant TA, Sandgren EP . 2000 Oncogene 19: 1092–1096

  • Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stemman G, Swisshelm K, Chen Z, Hendrix MJC, Pemberton P, Rafidi K, Ryan K . 1994 Cold Spring Harbor Symposium on Quantitative Biology LIX: 537–546

  • Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC . 1990 Cell 61: 1121–1135

  • Sheng S, Carey J, Seftor E, Dias L, Hendrix MJC, Sager R . 1996 Proc. Natl. Acad. Sci. USA 93: 11669–11674

  • Sheng S, Pemberton P, Sager R . 1994 J. Biol. Chem. 269: 30988–30993

  • Sheng S, Truong B, Frederickson D, Wu R, Pardee AB, Sager R . 1998 Proc. Natl. Acad. Sci. USA 95: 499–504

  • Sternlicht MD, Kedeshian P, Shao ZM, Safarians S, Barsky SH . 1997 Clin. Cancer Res. 3: 1949–1958

  • Wagner M, Greten FR, Weber CK, Koschnick S, Mattfeldt T, Deppert W, Kern H, Adler G, Schmid RM . 2001 Genes Dev. 15: 286–293

  • Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Naggar A, Hung MC . 2000 Oncogene 19: 2398–2403

  • Yamada N, Tamai Y, Miyamoto H, Nozaki M . 2000 Gene 11: 267–274

  • Zhang M, Magit D, Sager R . 1997a Proc. Natl. Acad. Sci. USA 94: 5673–5678

  • Zhang M, Sheng S, Mass N, Sager R . 1997b Mol. Med. 3: 49–59

  • Zhang M, Volpert O, Shi YH, Bouch N . 2000 Nat. Med. 6: 196–199

  • Zou Z, Anisowicz A, Hendrix MJC, Thor A, Neveu M, Sheng S, Radfidi K, Seftor E, Sager R . 1994 Science 263: 536–529

  • Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S . 2000 J. Biol. Chem. 275: 6051–6054

Download references

Acknowledgements

This work was supported in part by a Prostate Cancer Pilot Grant from National Cancer Institute/Wayne State University CA69845 (to S Sheng), a Ruth Sager Memorial Fund established by Dr Arthur B Pardee (to S Sheng), and by NIH grants CA 64248 and CA 83964 (to KB Reddy).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shijie Sheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reddy, K., McGowen, R., Schuger, L. et al. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model. Oncogene 20, 6538–6543 (2001). https://doi.org/10.1038/sj.onc.1204796

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204796

Keywords

This article is cited by

Search

Quick links